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Abstract
Introduction: Sepsis is an exaggerated and dysfunctional immune response to infection. Activation of innate immunity
recognition systems including complement and the Toll-like receptor family initiate this disproportionate inflammatory
response. The aim of this study was to explore the effect of combined inhibition of the complement component
C5 and the Toll-like receptor co-factor CD14 on survival, hemodynamic parameters and systemic inflammation
including complement activation in a clinically relevant porcine model of polymicrobial sepsis.
Methods: Norwegian landrace piglets (4 ± 0.5 kg) were blindly randomized to a treatment group (n = 12) receiving the
C5 inhibitor coversin (OmCI) and anti-CD14 or to a positive control group (n = 12) receiving saline. Under anesthesia,
sepsis was induced by a 2 cm cecal incision and the piglets were monitored in standard intensive care for 8 hours. Three
sham piglets had a laparotomy without cecal incision or treatment. Complement activation was measured as sC5b-9
using enzyme immunoassay. Cytokines were measured with multiplex technology.
Results: Combined C5 and CD14 inhibition significantly improved survival (p = 0.03). Nine piglets survived in
the treatment group and four in the control group. The treatment group had significantly lower pulmonary artery
pressure (p = 0.04) and ratio of pulmonary artery pressure to systemic artery pressure (p < 0.001). Plasma sC5b-9 levels
were significantly lower in the treatment group (p < 0.001) and correlated significantly with mortality (p = 0.006). IL-8
and IL-10 were significantly (p < 0.05) lower in the treatment group.
Conclusions: Combined inhibition of C5 and CD14 significantly improved survival, hemodynamic parameters and
inflammation in a blinded, randomized trial of porcine polymicrobial sepsis.
Introduction
Sepsis presents with the cardinal signs of inflammation
on the basis of a suspected or detected infective agent [1].
If left untreated, or treated too late, sepsis will progress to
a systemically uncontrolled, dysregulated immune re-
sponse leading to vascular instability, capillary leakage,
septic cardiomyopathy, shock, disseminated intravascular
coagulation, and acute kidney and respiratory failure. This
multiple organ failure (MOF) is associated with high costs
of care, and more importantly high rates of morbidity and
mortality [2, 3].
Despite much research and several attempts to provide
specific drug therapies the treatment is still early appli-
cation of broad-spectrum antibiotics and supportive
therapy [4]. With the withdrawal of Xigris (drotrecogin
alpha) in 2011, more effective and specific treatment
strategies of sepsis are needed [5]. There is also a need
for adequate experimental models of sepsis as the most
commonly used animal models have failed to mimic
human sepsis [6, 7].
Early studies focused on the endotoxic shock caused
by intravenous (IV) infusion of lipopolysaccharide (LPS),
bacterial infusions or cecal ligation and puncture (CLP)
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in smaller animals such as mice and rats. Now more elab-
orate, sophisticated, and clinically relevant models in lar-
ger animals are emerging [8]. In experimental sepsis the
model of cecal incision in pig overcomes several pitfalls.
Compared to rodents, pigs have a greater genetic, anatom-
ical and physiological resemblance to humans [9–11].
Furthermore, their size enables repeated blood sampling
for comprehensive analysis and the use of human medical
equipment. Finally, exposing the pig to its own microbiota
by cecal incision induces polymicrobial sepsis with a de-
fined site of infection, often lacking in other experimental
models. The model presented here is very close to clinical
conditions like intestinal leak during anastomotic insuffi-
ciency, bowel perforation or bacterial translocation follow-
ing conditions of sterile inflammation in the abdomen.
As the first line of defense, innate immunity acts upon
infection with activation through pattern recognition. In
sepsis, this activation is exaggerated and worsens the
disease through overproduction of multiple cytokines,
paracrine and autocrine factors. In numerous crisscross-
ing pathways the inflammatory network acts on the
vasculature and organs [10, 12]. In the early phase, the
Toll-like receptor (TLR) and complement systems
together constitute the primary pathways of danger rec-
ognition through pattern recognition receptors (PRRs)
and consequently, immune activation [13, 14]. The three
pathways of complement activation converge on compo-
nent C3, which proceeds to activate complement com-
ponent 5 (C5), generating C5a and the final, terminal
C5b-9 complement complex (TCC) and C5a has a docu-
mented, harmful role in sepsis [15]. Thus, C5 is a par-
ticularly interesting target for intervention in sepsis,
leaving C3 free to opsonize in microbial defense. Equally,
cluster of differentiation (CD)14 is an important core-
ceptor to several of the TLRs, including TLR4, TLR2,
TLR3, TLR7 and TLR9 [16].
We have therefore proposed inhibition of TLR and
complement as a treatment regimen to attenuate the
septic inflammatory response [17]. Recently, we showed
convincing data in a murine CLP model of sepsis that
supports this approach [18]. The aim of the current
study was to test our hypothesis by inhibiting both com-
plement and TLR. We specifically inhibited the key pro-
inflammatory components C5 and CD14 in a blinded,
randomized, prospective study of porcine polymicrobial
sepsis that closely mimics clinical sepsis.
Methods
Treatment reagents
Coversin, the 16.8 kDa, endotoxin-free recombinant
bacterial Ornithodoros moubata complement inhibitor
(OmCI; coversin) protein [19], was kindly provided by
Volution Immuno Pharmaceuticals Ltd (Coventry,
UK). The mouse anti-porcine CD14 IgG2/4 chimeric
monoclonal antibody clone rMIL-2 has been described in
detail previously [20] and was produced by Excellgene SA
(Monthey, Switzerland).
Animals, anesthesia and monitoring
Norwegian landrace piglets (Sus scrofa domesticus) (n = 24),
weighing 4 ± 0.5 kg were obtained from an authorized in-
dustrial pig producer. Approximately 2 mg/kg intranasal
midazolam was administered before gaining intravascular
access to an ear vein (2.5 mg/mL or 5 mg/mL). Piglets then
received 10–15 mg/kg ketamine prior to endotracheal
intubation with a 4.0 mm inner diameter tube with cuff.
After intubation, IV infusions of propofol (10 mg/kg/hr)
and fentanyl (50 μg/kg/hr) were initiated. Four piglets
received small IV boluses of pancuronium bromide when
shivering interfered with ventilation. Mechanical ventilation
was provided and the following volume-controlled mode
was used: tidal volume of 15–20 mL/kg, respiratory rate of
26 per minute, inspiratory/expiratory time ratio of 1:3, posi-
tive end-expiratory pressure of 0 cm H2O, and inspiratory
oxygen fraction of 0.3. The respiratory settings were ad-
justed to maintain pH at 7.4 only before the surgical cecal
incision. All subsequent changes in arterial blood gas values
were considered a result of sepsis, and the respiratory
settings were left unchanged. An arterial catheter was
surgically inserted into the internal carotid artery and a
5-French Edwards Swan-Ganz catheter (Baxter Healthcare
Corp., Irvine, CA, USA) was inserted in the external
jugular vein and advanced until a satisfactory pulmonary
artery occlusion pressure was obtained. All pressure trans-
ducers were zero-referenced to midchest level. With a
minimally invasive technique, a urinary catheter was
inserted during the laparotomy to monitor urinary output
and core temperature. Temperature, heart rate (HR),
mean systemic arterial pressure (MAP), mean pulmonary
artery pressure (MPAP), central venous pressure and pul-
monary artery occlusion pressure were displayed continu-
ously on a Siemens SC 8000 Patient Monitor (Healthcare
Diagnostics Ltd., Camberley, UK) and values recorded
every 5 minutes.
Animal model and experimental design
Piglets were allocated to receive either treatment (n = 12)
or saline as vehicle (n = 12) before surgical sepsis was
induced. Each week, two piglets were randomized as
matched pairs to maintain homogeneity in regard to
weight, age and gender, yielding 12 pairs of piglets receiv-
ing treatment or serving as the untreated counterpart. All
investigators participating in the experiment were blinded
to this allocation. Finally, three piglets served as sham
controls, having a laparotomy and cystotomy but not a
cecal incision. After baseline blood samples were obtained,
the interventional reagents were then administered as
follows: in the treatment group, an initial IV infusion of
Skjeflo et al. Critical Care  (2015) 19:415 Page 2 of 8
coversin (1 mg/kg) was delivered as a 5-minute bolus
followed by a second 5-minute bolus containing the mouse
anti-porcine CD14 monoclonal antibody (5 mg/kg). Imme-
diately after the anti-CD14 bolus, a continuous IV infusion
of coversin was initiated at 0.05 mg/kg/h and maintained
throughout the experiment. For the untreated group, saline
was administered in the exact same manner regarding
volume and infusion time.
Piglets then had a laparotomy with a 10 cm longitu-
dinal incision in the right lower lumbar region, the
cecum was localized and a 2 cm longitudinal incision
made. Intestinal content was allowed to leak into the ab-
dominal cavity before closing the abdomen in two layers,
as instructed by Kato and colleagues [8]. Piglets were
then observed until death or otherwise for 8 hours at
which point they were euthanized by propofol (50 mg),
fentanyl (200 μg), and KCl (10 mmol).
Blood samples
Blood samples were drawn at baseline (immediately after
IV access and before surgery) immediately after surgery
and 1.5, 3, 4, 5, 6 and 8 hours after surgery. From those
animals that died before 8 hours, a final sample was
drawn at death. Whole blood was used for arterial blood
gas analysis, performed on an Epoc reader (Epocal, Inc.,
Ottawa, ON, Canada). Hematological parameters includ-
ing hemoglobin, hematocrit, total leukocyte and platelet
counts were analyzed on a Siemens ADVIA 2120 instru-
ment (Siemens Healthcare Diagnostics Ltd., Camberley,
UK). Serum was obtained after clotting in gel tubes from
Greiner Bio-One GmbH (Frickenhausen, Germany).
Serum creatinine, alanine transaminase (ALT), aspartate
aminotransferase (AST), creatine kinase (CK), albumin
and total protein were analyzed using ADVIA®1800
(Siemens Medical Solutions Diagnostics, Japan) using
reagents from Siemens Healthcare Diagnostics Ltd.
(Camberley, UK).
Blood bacterial culture
Samples for detection of bacteria in blood were obtained
at baseline (before surgery) and at death using routine
sampling and assays according to the procedures at the
hospital's intensive care unit.
Complement activation and cytokines
EDTA-plasma was prepared by immediately placing the
blood sample on crushed ice. Within 30 minutes sam-
ples were centrifuged at 2500 × g for 15 minutes at 4 °C
and plasma immediately stored at −70 °C. Complement
activation was measured as the soluble TCC (sC5b-9)
using multiplex xMAP technology (Bio-Plex; Bio-Rad
Laboratories, Inc., Hercules, CA, USA) as previously de-
scribed [21]. Briefly, mouse anti C5b-9 Ab (clone aE11;
Diatec Monoclonals AS, Oslo, Norway) was coupled to
carboxylated magnetic beads (Bio-Plex Pro) using a Bio-
Plex amine coupling kit (Bio-Rad Laboratories, Inc.).
Coupled beads were then incubated with samples,
followed by biotinylated anti-C6 monoclonal antibody
(mAb) (Quidel, San Diego, CA, USA) and streptavidin-
PE (Bio-Rad Laboratories, Inc.). The international com-
plement standard number 2, recently described [22], was
used as the calibration curve. Measurement and data
analysis was performed with the Bio-Plex™ 200 system
and the Bio-Plex Manager software version 6.0. Porcine
cytokines (n = 9) were analyzed in plasma using a multi-
plex kit from Bio-Rad Laboratories, Inc. according to the
manufacturer’s instructions. The kit comprised the
following cytokines: interferon (IFN)-α, IFN-β, tumor
necrosis factor (TNF), interleukin (IL)-1β, IL-4, IL-6, IL-8,
IL-10 and IL-12p40.
Ethics
The animals were treated in accordance with the
Norwegian Laboratory Animal Regulations and the EU
directive 2010/64/EU. The Norwegian Animal Research
Authority approved the study.
Statistics
All statistics were performed using GraphPad Prism 6
for Mac (GraphPad Software, San Diego, CA, USA).
Serial measurements were analyzed by comparing
descriptive summary measures (means and differences
between maximum and minimum values) as described
for peaked and growth data [23]. Survival curves were
compared using log-rank (Mantel-Cox) test and correl-
ation was determined by calculating the Pearson coeffi-
cient. The treated group was compared to the untreated
group using the nonparametric Wilcoxon matched-pairs
signed-rank test according to the matched-pairs design
of the study. p < 0.05 was considered significant.
Results
Effect of treatment on survival during polymicrobial
sepsis
A significantly reduced mortality was observed in the
treated group where nine out of 12 animals survived
during the 8-hour observation period, compared to four
out of 12 in the nontreated group (p = 0.03) (Fig. 1). All
three uninfected (sham) animals survived throughout
the 8-hour observation time.
Effect of treatment on mean systemic and pulmonary
arterial pressure
Hemodynamic parameters were analyzed in search of an
explanation for the improved survival. Following surgery,
all animals with cecal perforation had a higher heart rate
(HR) (mean 183 bpm) compared to the animals in the
sham group (mean 134 bpm). The HR peaked 2 hours
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after perforation. Following a brief increase in mean
arterial pressure (MAP), both the treatment and the
control groups developed classical signs of septic shock
with a decrease in MAP (Fig. 2a). The mean pulmonary
arterial pressure (MPAP) increased substantially in the
nontreated group during the course (Fig. 2b). In
comparison, this increase was not shown in the treated
group (p = 0.04) (Fig. 2b). The MPAP/MAP ratio, reflect-
ing the changes in the normally low-pressure pulmonary
circuit compared to the normally high-pressure systemic
circuit, increased in both the treated and the untreated
group (Fig. 2c). Notably, the treated group had a
significantly lower mean MPAP/MAP ratio than the
untreated group (p = 0.016), and the ratio increased
significantly less than in the untreated group when
the trajectory of increase was compared by linear
regression (p < 0.001) (Fig. 2c).
Effect of complement activation on treatment and
survival
Seven of the eight animals in the untreated group that died
before scheduled euthanasia had exponentially increased
sC5b-9 levels (range 444–3713 complement arbitrary units
(CAU)/L). (Fig. 3a). sC5b-9 levels were significantly higher
in the untreated group compared to treated animals (p <
0.001, Fig. 3b). In the treated group, all but one animal had
a net decrease in sC5b-9 levels to below baseline values
throughout the experiment, consistent with a complete
blockade of C5 and thus no substrate for sC5b-9 gener-
ation. We then compared the levels of sC5b-9 to the out-
come for all 27 animals in a 2 × 2 plot using Fisher's exact
test for contingency, and found a significant association
between sC5b-9 levels and death (p = 0.006; odds ratio
(OR) 25.00; 95 % confidence interval (CI) 2.094 to 298.5).
Effect of complement and CD14 inhibition on
inflammation, hematology and clinical-chemical
parameters
The levels of IL-6, IL-8, IL-10, TNF and IL-12p40
increased in the untreated animals. A significant reduc-
tion of IL-8 (51 %) and IL-10 (39 %) (p < 0.05 for both)
was observed in the treatment group compared to the
untreated group (Fig. 4). Hematological and clinical-
chemical parameters were largely similar in the two
groups, except for a significantly lower mean total pro-
tein level in the treated group (Table 1).
Fig. 1 Effect of treatment with C5 and CD14 inhibitors on survival in
porcine polymicrobial sepsis. Piglets were randomized to receive
coversin (C5 inhibitor) and anti-CD14 as treatment (n = 12) or saline
(n = 12) in a cecal incision model of sepsis. Sham animals (n = 3) did
not undergo cecal incision and were included for reference. Mortality
was recorded during the 8-hour period and plotted as a Kaplan-Meier
curve. The curves were analyzed using the log-rank (Mantel-Cox) test.
C5 complement component 5, CD cluster of differentiation
Fig. 2 Effect of treatment with C5 and CD14 inhibitors on
hemodynamics in porcine polymicrobial sepsis. Mean systemic
arterial pressure (MAP) (panel a) and mean pulmonary artery
pressures (MPAP) (panel b) for each subject were recorded every
5 minutes. The plots represent mean values with corresponding
standard errors of means. The shaded area in panel b represents the
difference in mean MPAP whereas the mean ratio of the MPAP to MAP
is plotted in (panel c). Lines are drawn by simple linear regression. The
sham animal curve is included for reference. C5 complement
component 5, CD cluster of differentiation
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Bacteriology
Polymicrobial bacteremia was confirmed in selected
blood cultures revealing Escherichia coli and enterococci
in all samples. Varying amounts of Staphylococcus
aureus, streptococci and Klebsiella were also detected
(data not shown).
Discussion
The combined regimen of coversin and anti-CD14 was
recently proven effective in reducing the mortality in a
mouse CLP model [18]. However, in the present porcine
study, the transfer of these experiments to a surgically
relevant, human-like acute and severe septic state
revealed an improved survival in the treated group that
was greater than anticipated. Although all animals devel-
oped severe tachycardia and prolonged hypotension, a
remarkable difference between the two groups was
observed. These piglets were of the same age, gender and
farrow, selected at the same time of year with equal diets
and conditions before the experiment. Furthermore, the
animals were randomly selected as matched pairs, the
intervention was unknown to the investigators and the an-
imals received no other form of intervention or supportive
therapy than that described.
Our analysis revealed subtle but distinct differences in
MAP throughout the experiment but the greatest effect
was seen on MPAP and MPAP in relation to MAP. On
average, both groups had a lower MAP throughout the
experiment, but the untreated group showed a more rapid
decrease in MAP than the treated group. Clinically, both
groups developed septic shock. However, the untreated
group had a significantly greater increase in MPAP reach-
ing higher maximum values than the treated group.
Indeed, the MPAP in the treated group was comparable to
sham for a long time period of the experiment. Notably,
as shown by Kato and colleagues [8], the MPAP to MAP
ratio can be calculated to reveal changes in both systemic
and pulmonary circulation in sepsis; as the systemic
pressure falls and the pulmonary pressure increases, the
two merge as the factor approaches 1.0. In our study, the
dynamic increase of MPAP in relation to decrease in
MAP was significantly less pronounced in the treated
group, underscoring a beneficial effect of blocking C5 and
CD14 on the hemodynamic parameters.
Fig. 3 Effect of treatment with C5 and CD14 inhibitors on complement
activation in porcine polymicrobial sepsis. The plasma concentration of
sC5b-9 was determined every 90 minutes during the 8-hour observation
and additional samples were obtained from animals that died before the
end of the observation period (panel a). The difference in mean increase
from minimum to maximum values of complement activation between
the treated and control groups are shown in (panel b). The sham animal
data is included for reference. † = death before the end of the
observation period. CAU = complement arbitrary units, see ref.
[22]. C5 complement component 5, CD cluster of differentiation,
sC5b-9 soluble terminal C5b-9 complement complex
Fig. 4 Effect of treatment with C5 and CD14 inhibitors on IL-8 and
IL-10 in porcine polymicrobial sepsis. Plasma cytokines were measured
during the observation period. The difference in mean increase from
minimum to maximum values of plasma IL-8 and IL-10 are shown. The
sham animal data is included for reference. C5 complement component
5, CD cluster of differentiation, IL interleukin
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In contrast to humans, pigs harbor large amounts of pul-
monary intravascular macrophages serving as the predom-
inant part of the mononuclear phagocytic system [24].
There are several reports on porcine pulmonary hyperten-
sion following infusion of endotoxin [25, 26] triggering the
release of prostaglandins, leukotrienes and other vasoactive
mediators from macrophages. In this study, we can specu-
late that the combined treatment abolished recognition of
endotoxin and other pathogen-associated molecular pat-
terns, thus reducing the ensuing inflammation and vaso-
constriction. The described leukotriene B4 (LTB4) capture
by coversin could also enhance this effect.
Coversin has an internal binding pocket capturing LTB4
[27] and thus has the potential to reduce LTB4-dependent
effects in sepsis. In turn, LTB4 promotes neutrophil
chemotaxis, increases adherence to capillary walls and
may directly induce pulmonary arterial hypertension [28].
In sepsis, neutrophil-mediated tissue injury often affects
remote organs, particularly the lungs. In this context, im-
paired lung function often correlates with the intensity of
neutrophilic infiltrates [29]. As coversin’s C5 and LTB4
binding activities are considered independent, producing a
type of coversin that inhibits C5 but is unable to bind
LTB4 could be used to further explore the selective
contribution of LTB4 in this model [27].
Complement activation was markedly increased in the
untreated group whereas it was nonexistent or even
decreased in the treated group, consistent with a
complete block of C5 and thus no substrate for sC5b-9
formation. Excessive systemic complement activation
with liberation of C5a has a number of concomitant
detrimental effects both directly and through other inflam-
matory and hemostatic mediators [30]. Thus, complement-
mediated endothelial cell activation, which was not
measured in the present study, could likely have contributed
to prothrombotic activity leading to intravascular coagula-
tion. This would eventually reduce tissue perfusion and con-
tribute to the hemodynamic instability subsequently leading
to organ failure. Within the short observation time, all
animals that died in the untreated group had substantially
elevated sC5b-9 levels, consistently escalating before death.
In return, three of the four animals that survived in the
untreated group did not show this increase. Arguably, the
anticipated lack of activation could have protected the
treated group by lowering ischemia-induced inflammation
during shock. In this line of thought, complement activation
can be considered as a cause of increased morbidity and
mortality in the untreated group. As a limitation of the
study, a direct causal effect of complement activation alone
cannot be proven from the present data. However, the in-
crease in the activation product sC5b-9 seems to be a good
marker for the processes affecting outcome. A similar close
and highly significant correlation has been described be-
tween the levels of plasma sC5-9 in patients admitted to
hospital with Neisseria meningitidis sepsis and the mortality
during the course of this disease [31].
Downstream effects of complement and TLR activation
include the release of cytokines and chemokines. We
therefore examined whether inhibition of complement and
CD14 would have any effect on these inflammatory media-
tors. We documented a modest but distinct increase in
several cytokines during the course of sepsis. Importantly,
for IL-8 and IL-10, this increase was significantly less pro-
nounced for the treated group, indicating an early effect of
the treatment regimen on these two key cytokines.
Increased levels of both the proinflammatory chemokine
IL-8 and the anti-inflammatory cytokine IL-10 have been
associated with severe sepsis and poor outcome [32–34].
In models of both Gram-negative and Gram-positive
bacteria-induced inflammation they are both highly
Table 1 Comparison of hematological and clinical-chemical parameters in treated (coversin + anti-CD14) and untreated (Nacl) groups of
piglets with polymicrobial sepsis
NaCl Coversin + anti-CD14 Untreated vs. treated
Changea (Meanc) Change (Mean) Difference (Mean diff.) P-valueb (P-valued)
Hemoglobin (g/dL) 2.2 ± 0.21 (10) 2.2 ± 0.28 (10) 0.0 ± 0.35 (0) 0.87 (0.42)
Leukocytes (109/L) 5.7 ± 0.89 (5.8) 5.8 ± 0.78 (5.9) 0.1 ± 1.38 (0.1) >0.99 (>0.99)
Thrombocytes (109/L) 205 ± 37 (296) 198 ± 33 (230) 7 ± 37 (66) 0.78 (0.30)
Creatinine (μmol/L) 64 ± 8.9 (79) 73 ± 6.5 (88) 9 ± 7.2 (9) 0.15 (0.18)
ALAT (U/L) 18 ± 8.2 (43) 14 ± 2.3 (39) 4 ± 9.3 (4) 0.41 (0.91)
ASAT (U/L) 99 ± 21 (54) 94 ± 16 (52) 5 ± 30 (2) 0.81 (0.85)
Creatinine kinase (U/L) 305 ± 57 (448) 434 ± 69 (513) 129 ± 63 (65) 0.13 (0.30)
Albumin (g/L) 8.1 ± 0.6 (24) 10 ± 0.8 (23) 1.9 ± 1.2 (1) 0.20 (0.18)
Total protein (g/L) 12 ± 1.1 (37) 15 ± 1.5 (34) 3 ± 2.0 (3) 0.27 (0.02*)
aChange represents the difference between maximum and minimum values ± SEM
bThe difference in change in the two groups was compared using Wilcoxon matched-pairs signed rank test
cMean level throughout the experiment
dThe difference in means (mean diff.) in the two groups was also compared using the Wilcoxon matched-pairs signed rank test. * P < 0.05 was considered significant
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dependent on activation of complement and CD14, IL-8
being relatively more complement-dependent [35, 36]. This
is in accordance with our present findings in polymicrobial
sepsis where complement activation was completely
abolished in the treated group, which probably is a main
explanation for the reduced IL-8 release, although an add-
itional effect of blocking CD14 is likely for both mediators.
In order to attenuate the proinflammatory cytokine storm
as well as the anti-inflammatory immunosuppressive state,
we claim that early reduction of IL-8 and IL-10 might be
beneficial in sepsis.
In the present study, however, the cytokine response
was generally less pronounced than expected from such
an aggressive model. This suggests that the rapid and
extensive complement activation per se may play a major
role at this early stage where the full-fledged systemic
inflammatory response syndrome (SIRS) and associated
MOF did not have time to fully develop. Accordingly,
few differences were seen in the hematological and
clinical-chemical parameters reflecting organ damage.
Yet, the unique finding of reduced mean total protein
in the untreated group could be an early sign of capil-
lary leak and therefore endothelial barrier dysfunction,
which reportedly is one of the most important patho-
physiological mechanisms in sepsis [37]. We do admit
that the relatively short observational period as well as
demanding nonparametric statistical analysis with
increased risk of type II errors should be taken into
consideration when interpreting the data.
Lastly, the blood cultures revealed growth of both
Gram-negative and Gram-positive bacteria, indicating a
clinically relevant model of polymicrobial sepsis. We have
previously shown that combined C5 and CD14 inhibition
efficiently inhibits inflammation induced by both Gram-
negative [38] and Gram-positive [36] bacteria. Further-
more, we have shown that this combined inhibition, but
not single inhibition of C5 and CD14, increased survival
in a mouse CLP model [18]. In the present study we docu-
ment for the first time that the combined regimen works
in a large animal model of sepsis. It resembles human
disease more closely and is clinically most relevant. The
limited amount of inhibitors available and their high costs
precluded us, however, from using adult pigs. Thus, the
use of small piglets makes this model more relevant for
neonatal sepsis than for adult sepsis, which also should be
taken into consideration when interpreting the data.
Finally, the fact that treatment was started at baseline,
according with the “proof-of principle” of the protocol, is
a limitation of the study with respect to clinical relevance
for established sepsis. Recent data obtained in vitro using
the combined complement- and CD14-inhibitory regimen
“post challenge” indicates that a “therapeutic window”
might exist [39], though an efficient effect of delayed
treatment in vivo remains to be shown.
Conclusions
From the results of the present study it is tempting to
speculate that the combined inhibition of C5 and CD14
reduced the innate immune response to the extracom-
partmental gastrointestinal flora of the piglets, in turn
reducing the derangement of the pulmonary circulation
and thereby improving survival in this robust 8-hour
model of sepsis. The need for antibiotic therapy in a
clinical situation is obvious. Our hypothesis merits
further testing in larger, longer and more comprehensive
trials where the combined regimen we describe here is
used to supplement conventional therapy.
Key messages
 Treatment of sepsis is largely limited to antibiotics
and supportive therapy. New specific treatment
strategies are demanded as well as experimental
models relevant for human sepsis.
 Systemic inhibition of two innate immune recognition
systems was tested as a therapeutic strategy in a
clinically relevant porcine model of sepsis.
 Combined inhibition of the complement component
C5 and the TLR coreceptor CD14 abrogated
complement activation, attenuated physiological
derangements, reduced cytokine release and improved
survival in a porcine model of polymicrobial sepsis.
 This broad-acting “upstream” inhibition of innate
immunity might be a therapeutic approach to human
sepsis, where inhibition of “downstream” single
inflammatory mediators has failed.
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